In addition to being a senior investigator at the CHU de Quebec–Université Laval Research Center and professor in the Faculty of Pharmacy at Laval University, Dr. Di Paolo is also an associate professor at the University of Saskatchewan, Saskatoon, Canada. She received the Janssen-Ortho pharmaceutical research award from the Association of Faculties of Pharmacy of Canada (2002); the Heinz Lehmann prize from the Canadian College of Neuopsychopharmacology, 2003; distinctions: Femmes réussite region Chaudière Appalache, Journal Économique de Québec, 2004, Femme de mérite, YWCA of Québec, Science and technology category, 2006, Empreintes d’elles, YWCA, honoring 400 women, 400th anniversary of Québec City, 2008 and the Diamond prize for excellence in Fundamental Research, Centre Hospitalier Universitaire de Québec, Québec City, 2015.

Dr. Di Paolo has published over 295 peer-reviewed articles and 470 summaries. Her research interest is on Parkinson’s disease and L-Dopa-induced dyskinesias in the post-mortem human brains of Parkinson’s disease patients, non-human primates, and rodent models of Parkinson. This research was and is currently funded by the CIHR, NSERC, Parkinson Society Canada, CQDM, NIH and contracts from Prexton Therapeutics, Novartis, and Merck Serono. 

In recent years, her research has focused on the glutamatergic neurotransmission and the implication of ionotropic and metabotropic glutamate receptors. Various specific antagonists, positive and negative allosteric modulators of glutamate receptors were investigated to inhibit or prevent the development of L-Dopa-induced dyskinesias. Drugs of various pharmacological activities are also investigated in her laboratory including, serotoninergic drugs, omega-3, plasmalogens and dehydroepiandrosterone (DHEA). She recently investigated the effect of a subthalamic lesion on L-Dopa-induced dyskinesias in parkinsonian monkeys, and is now working on the effect of deep stimulation in this area of the brain.

A major research endeavour in her laboratory is also to investigate neuroprotection in a mouse model of Parkinson’s Disease. Repurposing drugs used to treat various endocrine conditions were found to be neuroprotective such as estrogen, progesterone, the selective estrogen receptor modulator raloxifene, and the 5α-reductase inhibitor, dutasteride. Novel non-genomic mechanisms of action were investigated in this neuroprotection, including the implication of the membrane estrogen receptor (GPER1) and the effect of cholesterol on membrane microviscosity.

2705, boulevard Laurier
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

275 entries « 28 of 28 »

Di Paolo T, Sandorfy C

Hydrogen bond breaking potency to fluorocarbon anesthetics.

Journal Article

J Med Chem, 17 (8), pp. 809-14, 1974, ISSN: 0022-2623.

| Links:

Di Paolo T, Sandorfy C

On the hydrogen bond breaking ability of fluorocarbons containing higher halogens

Journal Article

Can J Chem, 52 , pp. 3612-3622, 1974, ISSN: 0008-4042.

Di Paolo T, Sandorfy C

On the biological importance of the hydrogen bond breaking potency of fluorocarbons

Journal Article

Chem Phys Lett, 26 , pp. 466-469, 1974, ISSN: 0009-2614.

Di Paolo T, Sandorfy C

Low temperature infrared study of hydrogen bonding in acetone oxime-d6

Journal Article

Can J Chem, 51 , pp. 1441-1442, 1973, ISSN: 0008-4042.

Di Paolo T, Bourderon C, Sandorfy C

Model calculations on the influence of mechanical and electrical anharmonicity on infrared intensities : relation to hydrogen bonding

Journal Article

Can J Chem, 50 , pp. 3161-3166, 1972, ISSN: 0008-4042.

275 entries « 28 of 28 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2023-05-01
  • Sex-specific investigations of Parkinson's disease mouse models: application for gonadal drugs repurposing, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-10-01 to 2023-03-31

Recently finished projects

  • Mechanisms of therapeutic efficacy of deep brain stimulation in Parkinson's disease, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30
  • Role of 5-alpha reductase 1 in the treatment of neurodegeneration and levodopa-induced dyskinesias, Subvention, Michael J. Fox Foundation for Parkinson's Research, Target Advancement Program, from 2018-09-01 to 2019-08-31
  • Sex-specific investigations of Parkinson's disease mouse models: application for gonadal drugs repurposing, Subvention, Instituts de recherche en santé du Canada, Subvention de catalyseur : Intégrer le sexe comme variable dans la recherche biomédicale, from 2018-04-01 to 2020-03-31
Data provided by the Université Laval research projects registery